These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
340 related items for PubMed ID: 20110001
21. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504 [Abstract] [Full Text] [Related]
22. Livedoid skin reaction probably due to imatinib therapy. Martínez-González MC, del Pozo J, Yebra-Pimentel MT, Pérez M, Almagro M, Fonseca E. Ann Pharmacother; 2007 Jan; 41(1):148-52. PubMed ID: 17190842 [Abstract] [Full Text] [Related]
23. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Kolb EA, Pan Q, Ladanyi M, Steinherz PG. Cancer; 2003 Dec 15; 98(12):2643-50. PubMed ID: 14669284 [Abstract] [Full Text] [Related]
25. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A. Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376 [Abstract] [Full Text] [Related]
26. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H. Ann Hematol; 2006 Dec 15; 85(12):841-7. PubMed ID: 17006667 [Abstract] [Full Text] [Related]
30. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Gadzicki D, von Neuhoff N, Steinemann D, Just M, Büsche G, Kreipe H, Wilkens L, Schlegelberger B. Cancer Genet Cytogenet; 2005 Jun 15; 159(2):164-7. PubMed ID: 15899391 [Abstract] [Full Text] [Related]
33. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha. Tóthová E, Kafková A, Fricová M, Benová B, Kirschnerová G, Tóthová A. Neoplasma; 2005 Jun 15; 52(1):63-7. PubMed ID: 15739029 [Abstract] [Full Text] [Related]
35. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma. Ahmed MS, Kroft SH, Davis NB, King DM, Cheng YC. Leuk Res; 2008 Sep 15; 32(9):1476-9. PubMed ID: 18308388 [Abstract] [Full Text] [Related]
37. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months. Michael M, Antoniades M, Lemesiou E, Papaminas N, Melanthiou F. Oncologist; 2009 Dec 15; 14(12):1198-200. PubMed ID: 19955186 [Abstract] [Full Text] [Related]
38. Imatinib mesylate for the treatment of chronic myeloid leukemia. Soverini S, Martinelli G, Iacobucci I, Baccarani M. Expert Rev Anticancer Ther; 2008 Jun 15; 8(6):853-64. PubMed ID: 18533795 [Abstract] [Full Text] [Related]